AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33284201
Drug: Delaying parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delaying parenteral nutrition to day 8 of admission
Trial: 33284201
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high doses of amino acids (>3.5 g/kg/day) immediately after birth
Trial: 33284201
Drug: Commencing parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commencing parenteral nutrition on the first day of life
Trial: 33284201
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition after 72 hours if enteral feeds are not tolerated
Trial: 33284201
Drug: Avoiding parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoiding parenteral nutrition within 24 hours of admission
Trial: 32502443
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg) plus Bevacizumab (15 mg/kg) every 3 weeks
Trial: 35536730
Drug: Intraoperative pectoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative pectoral nerve block (PECS) with 10 ml of 0.5% bupivacaine
Trial: 35536730
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided thoracic paravertebral block (TPV) with 25 ml of 0.25% bupivacaine at T3 level
Trial: 33715994
Drug: Mannitol 400
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol 400 mg BID
Trial: 36731588
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) treatment
Trial: 35553959
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment for three days
Trial: 32899094
Drug: Ropivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.125% + dexmedetomidine 0.5 μg/mL (RD1 group)
Trial: 32899094
Drug: Ropivacaine 0.08%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.08% + dexmedetomidine 0.5 μg/mL (RD2 group)
Trial: 32899094
Drug: Ropivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.125% + sufentanil 0.5 μg/mL (RS1 group)
Trial: 32899094
Drug: Ropivacaine 0.08%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.08% + sufentanil 0.5 μg/mL (RS2 group)
Trial: 32339499
Drug: Intravenous ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ghrelin (3 mcg/kg loading dose followed by 16.9 ng/kg/min infusion)
Trial: 32339499
Drug: Oral ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ghrelin receptor blocker (PF-5190457)
Trial: 33546069
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 μg/kg 5 minutes after anesthesia induction
Trial: 33473242
Drug: Commiphora molmol
RxNorm normalized name: Commiphora molmol resin
DrugBank: Myrrh (DB11605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commiphora molmol (myrrh) mouthwash used twice a day for 7 days
Trial: 33473242
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline mouthwash used twice a day for 7 days
Trial: 36088783
Drug: Advice in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice in combination with blood flow restriction training (BFRT)
Trial: 34143971
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus IBI305 (200 mg every 3 weeks and 15 mg/kg every 3 weeks respectively)
Trial: 34170062
Drug: Individualized medical
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized medical therapy
Trial: 32196506
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of praziquantel (40 mg/kg)
Trial: 32196506
Drug: Four repeated
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four repeated doses of praziquantel (40 mg/kg) administered at two-week intervals
Trial: 35209934
Drug: Fecal microbiota
RxNorm normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbiota transplantation (FMT) capsules taken orally on day 1, day 7, and day 14
Trial: 35209934
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken orally on day 1, day 7, and day 14
Trial: 32917259
Drug: Flow-controlled ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow-controlled ventilation for 48 hours with settings starting at pre-existing PEEP, tidal volume of 6 ml/kg lean body mass, and respiratory rate to maintain arterial pH above 7.2.
Trial: 35032379
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% and Bupivacaine 0.25% with 25 μg of Epinephrine
Trial: 34787868
Drug: Logotherapy (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Logotherapy (10 sessions, 90 min each, twice a week)
Trial: 35366664
Drug: Alternating doses
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating doses of pentazocine and acetaminophen
Trial: 33525480
Drug: Multicolored leaves
RxNorm normalized name: digitalis leaves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multicolored leaves (ML)
Trial: 33902293
Drug: Bach flower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bach flower remedies (BFR) - 30% hydro-brandy solution with two drops each of Impatiens, White Chestnut, Cherry Plum, Chicory, Crab Apple, and Pine, orally ingested (4 drops, 4 times a day for 4 weeks)
Trial: 33595680
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (specific treatment not detailed)
Trial: 33595680
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (specific treatment not detailed)
Trial: 35820629
Drug: KL130008 (1–20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KL130008 (1–20 mg single doses or 2–6 mg multiple doses once daily for seven days)
Trial: 34548526
Drug: Individually calculated
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually calculated loading regimen (weekly capsules)
Trial: 34548526
Drug: Monthly drinking
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly drinking solution (24,000 IU vitamin D)
Trial: 34548526
Drug: Monthly capsules
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly capsules (24,000 IU vitamin D)
Trial: 38115002
Drug: RTS,S vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S vaccine
Trial: 32389453
Drug: Remifentanil effect-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil effect-site concentration 1 ng/mL
Trial: 32389453
Drug: Remifentanil effect-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil effect-site concentration 2 ng/mL
Trial: 32389453
Drug: Remifentanil effect-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil effect-site concentration 3 ng/mL
Trial: 38184008
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice daily for 7 days
Trial: 34331551
Drug: Indobufen 100
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen 100 mg twice daily for 1 month
Trial: 34331551
Drug: Aspirin 50
RxNorm normalized name: aspirin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 50 mg twice daily, 75 mg once daily, 50 mg once daily
Trial: 34331551
Drug: Aspirin given
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin given every second or third day
Trial: 39110846
Drug: Vortioxetine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vortioxetine (5-20 mg/day)
Trial: 34488408
Drug: Six-month anti-TB
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-month anti-TB therapy
Trial: 34488408
Drug: Nine-month anti-TB
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine-month anti-TB therapy
Trial: 35892319
Drug: Enhanced upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced upper extremity therapy
Trial: 33360679
Drug: ASK120067 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASK120067 (oral irreversible tyrosine kinase inhibitor)
Trial: 33360679
Drug: ASK120067 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASK120067 (oral administration)
Trial: 33788609
Drug: Drug therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapies (acetaminophen, NSAIDs, opioids, benzodiazepines, Gabapentin, Neurontin, cortisone injections)
Trial: 33788609
Drug: Nondrug therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondrug therapies (self-care treatments, massage, acupuncture, spinal manipulation, physical therapy)
Trial: 33788609
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment recommendations
Trial: 33788609
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to treatment recommendations
Trial: 35160276
Drug: Carbohydrate-enriched drink
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-enriched drink (NutriciaTM Pre-op®) 400 mL
Trial: 32842315
Drug: 250 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg of CpG ODN recombinant (Hansenula polymorpha) Hepatitis B vaccine
Trial: 32842315
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg of commercial Hepatitis B vaccine
Trial: 33806310
Drug: Daratumumab alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab alone or as part of combination regimens
Trial: 34418903
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg orally for 2 weeks, taken half an hour before bedtime in low light conditions)
Trial: 34418903
Drug: Control (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (regular medications)
Trial: 34705072
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PRP (n: 62)
Trial: 34705072
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of PRP (n: 63)
Trial: 34705072
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of sodium saline (NS) (n: 59)
Trial: 34705072
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of sodium saline (NS) (n: 53)
Trial: 33579594
Drug: Dosage
RxNorm normalized name: Note Dosage Strength Label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage
Trial: 36210434
Drug: Differentiated digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differentiated digital intervention (ART medication messages, medication reminders, peer education, online discussion)
Trial: 34134469
Drug: Extended maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended maintenance with subcutaneous rituximab, n=138
Trial: 33782116
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (left-leaning and right-leaning media)
Trial: 32641226
Drug: Sacubitril/Valsartan (S/V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan (S/V) titrated to 97 mg/103 mg twice daily
Trial: 34496085
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics (2g amoxicillin preoperatively and 500mg tid for 7 days postoperatively)
Trial: 34496085
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same preoperative dose of amoxicillin and placebo postoperatively)
Trial: 34496085
Drug: Implant survival
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant survival rate
Trial: 32224896
Drug: Paclitaxel-Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel-Cisplatin (80 mg/m2 weekly + 20 mg/m2 triweekly cisplatin)
Trial: 32224896
Drug: Paclitaxel-Carboplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel-Carboplatin (80 mg/m2 weekly + AUC 5 triweekly carboplatin)
Trial: 32224896
Drug: Chemotherapy duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy duration >21 weeks
Trial: 32100494
Drug: Electronic moxibustion
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic moxibustion at Lianquan (CV 23), Tiantu (CV 22), Tianding (LI 17), and Futu (LI 18), 30 min each treatment, 5 times a week for 4 weeks.
Trial: 32100494
Drug: Routine medical
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medical treatment, acupuncture treatment, and swallowing rehabilitation training.
Trial: 35261120
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (400 mcg every 6 h up to 48 h)
Trial: 35261120
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (starting with 50 units up to a maximum of 300 units)
Trial: 35261120
Drug: Vaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal misoprostol (second-line treatment)
Trial: 35261120
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (second-line treatment)
Trial: 32098758
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg sprifermin every 6 months (q6mo)
Trial: 32098758
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg sprifermin every 6 months (q6mo)
Trial: 32098758
Drug: 100 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 µg sprifermin every 12 months (q12mo)
Trial: 34481898
Drug: Best endovascular
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best endovascular treatment (BET)
Trial: 33055007
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in NLR early during chemotherapy
Trial: 33847362
Drug: Cytisinicline 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisinicline 1.5 mg
Trial: 33847362
Drug: Cytisinicline 3
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisinicline 3 mg
Trial: 33847362
Drug: Cytisinicline 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisinicline 1.5 mg TID
Trial: 33847362
Drug: Cytisinicline 3
RxNorm normalized name: cytisinicline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytisinicline 3 mg TID
Trial: 35057084
Drug: Placebo—oral (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo—oral (Group A)
Trial: 35057084
Drug: Placebo—sublingual (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo—sublingual (Group B)
Trial: 35057084
Drug: Oral standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral standard aspirin—100 mg daily (Group C)
Trial: 35057084
Drug: Oral standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral standard aspirin—50 mg daily (Group D)
Trial: 35057084
Drug: Standard sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sublingual aspirin—100 mg (Group E)
Trial: 35057084
Drug: Standard sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sublingual aspirin—50 mg (Group F)
Trial: 35057084
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of micronized collagen-cogrinded aspirin (Groups G and H)
Trial: 35057084
Drug: Sublingual collagen-cogrinded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual collagen-cogrinded aspirin—100 mg (Group I)
Trial: 35057084
Drug: Sublingual collagen-cogrinded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual collagen-cogrinded aspirin—50 mg (Group L)
Trial: 33225464
Drug: Electric toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric toothbrush (Oral-B Kids)
Trial: 35938597
Drug: Boosted darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs)
Trial: 35732751
Drug: ZoneX #2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZoneX #2 (5.8 mg nicotine/pouch)
Trial: 35732751
Drug: ZoneX #3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZoneX #3 (10.1 mg nicotine/pouch)
Trial: 33771837
Drug: Inebilizumab 300
RxNorm normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inebilizumab 300 mg
Trial: 35460388
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral iron therapy (2*80 mg iron sulfate)
Trial: 35460388
Drug: Every other
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every other day oral iron therapy (2*80 mg iron sulfate)
Trial: 35156503
Drug: Recreational music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recreational music therapy (RMT)
Trial: 32301116
Drug: Identifying treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identifying treatment effect modifiers
Trial: 33917201
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) treatment
Trial: 34661821
Drug: Abemaciclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib plus NSAIs (150 mg)
Trial: 34661821
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus NSAIs (150 mg)
Trial: 32092505
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice daily plus aspirin (dual pathway inhibition regimen)
Trial: 34844156
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (0.3 g/kg body weight/day for 14 days)
Trial: 34844156
Drug: Control (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (25 g of sugar in 250 mL of water)
Trial: 33092558
Drug: Conditional cash
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditional cash incentive for education (education treatment arm)
Trial: 33092558
Drug: Conditional raffle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditional raffle for testing negative for curable STIs (in both education treatment and control arms)
Trial: 35305955
Drug: LABR‐312 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABR‐312 infusion (0.01 mg, 0.03 mg, and 0.08 mg)
Trial: 35700588
Drug: Immunomodulating (IM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulating (IM) supplements
Trial: 35700588
Drug: High-protein (HP)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein (HP) supplements
Trial: 34554208
Drug: Ivosidenib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivosidenib (500 mg, once daily)
Trial: 32350174
Drug: CHO gel
RxNorm normalized name: G-CSF (CHO cell derived)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO gel (commercially available jelly drink)
Trial: 33030273
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (350 mg/day)
Trial: 32396017
Drug: New Zealand
RxNorm normalized name: NEW ZEALAND GREEN MUSSEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New Zealand blackcurrant (NZBC) extract (two capsules of 300 mg each, 7-day intake)
Trial: 36149885
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2.5 mg letrozole and 50 mg clomiphene (CC)